Investigating gene expression profile of non-small cell lung cancer

Open Medicine ◽  
2011 ◽  
Vol 6 (5) ◽  
pp. 608-615
Author(s):  
Tõnu Vooder ◽  
Andres Metspalu
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Survival Rate ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Treatment Strategies ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers

AbstractLung cancer is mainly a lifestyle-associated disease with poor prognosis and the lowest five year survival rate of all types of cancer. Lung cancers are divided into two main groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Surgical treatment is generally indicated in cases of early stage NSCLC, and those patients treated with radical and aggressive surgery have a somewhat better survival rate. The main problems with lung cancer treatment are due to late diagnosis, rapidly developing drug resistance and side effects of the treatment that are experienced by almost all patients. The next step for distinguishing histologically complicated lung cancers and determining optimal treatment strategies is gene expression analysis. Supported by gene expression data, it is possible to prognosticate the course of the disease.

scholarly journals Small cell lung cancer transformation during antitumor therapies: A systematic review

Open Medicine ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. 1160-1167
Author(s):  
Xing Chai ◽  
Xinru Zhang ◽  
Wenqian Li ◽  
Jin Chai
Keyword(s):  
Lung Cancer ◽  
Drug Resistance ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Strategies ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Histological Transformation ◽  
Nsclc Patients

Abstract Lung cancer is the most common cause of cancer-related death. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the two major histological categories of lung cancers. Drug resistance is a great challenge for cancer treatment, and histological transformation from NSCLC to SCLC is one of the mechanisms underlying drug resistance in NSCLC patients. SCLC-transformed patients show combined characteristics of NSCLC and SCLC; however, they lack timely diagnoses and effective treatment strategies. Thus, we reviewed the clinical characteristics of SCLC transformation patients with a literature search to enhance clinical consciousness, diagnosis, and personalized treatment for patients with it.

scholarly journals Mortalin overexpression predicts poor prognosis in early stage of non–small cell lung cancer

Tumor Biology ◽  
2017 ◽  
Vol 39 (3) ◽  
pp. 101042831769591 ◽  
Author(s):  
Jie Sun ◽  
Shuan-Long Che ◽  
Jun-Jie Piao ◽  
Ming Xu ◽  
Li-Yan Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Survival Analysis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Normal Lung ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Prognostic Evaluation

Mortalin is a member of the heat shock protein 70 family, which is involved in multiple cellular processes and may play key roles in promoting carcinogenesis. This study attempted to identify the clinical consequences of Mortalin overexpression and its roles in the prognostic evaluation of non–small cell lung cancer. A total of 120 non–small cell lung cancer samples paired with the adjacent non-tumor tissue samples and 10 normal lung tissues were selected for immunohistochemical staining for Mortalin. The localization of Mortalin was detected in A549 non–small cell lung cancer cells using immunofluorescence staining. The correlations between Mortalin overexpression and the clinical features of non–small cell lung cancers were evaluated using the chi-square test. The survival analysis was calculated via the Kaplan–Meier method and the Cox proportional hazard models. Our studies suggested that Mortalin exhibited a primarily cytoplasmic staining pattern in the non–small cell lung cancers. The rate of strongly positive Mortalin expression was higher in the non–small cell lung cancer samples than in the adjacent non-tumor samples or in normal lung tissues. Mortalin overexpression was significantly correlated with high histological grades, advanced stages, lymph node metastases, and lower disease-free survival and overall survival rates of the patients with non–small cell lung cancer. The survival analysis demonstrated that Mortalin overexpression was a significant independent prognostic factor in non–small cell lung cancer, especially for patients with early stage of non–small cell lung cancer. In conclusion, Mortalin is up-regulated in non–small cell lung cancer, and it may be a potential biomarker of prognostic evaluation and a molecular therapeutic target for patients with early stage of non–small cell lung cancer.

Survivin gene expression in early-stage non-small cell lung cancer

2003 ◽  
Vol 200 (5) ◽  
pp. 620-626 ◽  
Author(s):  
Monica Falleni ◽  
Caterina Pellegrini ◽  
Antonio Marchetti ◽  
Barbara Oprandi ◽  
Fiamma Buttitta ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung ◽  
Survivin Gene

scholarly journals IS GAMMA-GLUTAMYL TRANSFERASE A PROGNOSTIC INDICATOR FOR EARLY-STAGE LUNG CANCER TREATED SURGICALLY?

2021 ◽  
Vol 74 (8) ◽  
pp. 1804-1808
Author(s):  
Muhammet Sayan ◽  
Dilvin Ozkan ◽  
Aykut Kankoc ◽  
Ismail Tombul ◽  
Ali Celik ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Prognostic Indicator ◽  
Small Cell ◽  
Gamma Glutamyl Transferase ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Glutamyl Transferase

The aim: Gamma-glutamyl transferase (GGT) is a membrane-dependent enzyme and is primarily involved in glutathione metabolism. While a correlation between high GGT levels and oxidative stress, cardiovascular diseases, and some cancers has been shown in the literature, its prognostic effect in patients with non-small-cell lung cancer remains unclear. The aim of this study was to investigate the correlation between the preoperative GGT levels and the prognosis of non-small-cell lung cancers treated surgically. Materials and methods: Following the approval of the loc al ethics committee, the medical records of patients surgically treated in our department for stage-I non-small-cell lung cancer between January 2010 and December 2019 were retrospectively reviewed. The patients were classified into a high group (high-GGT) and low group (low-GGT) according to the preoperative GGT cut-off levels, which were specific to our series and calculated by receiver operating characteristic (ROC) analysis. Survival differences between the groups were also investigated by Kaplan-Meier, log-rank, and Cox regression tests. Results: A total of 219 patients fulfilled the inclusion criteria and were included in the study. The median survival was 75 (range: 58.4–91.1) months in the high-GGT group and 91 (range: 85–96.8) months in the low-GGT group, and this difference was statistically significant (Hazard Ratio: 2.0, 95% CI 1.0-3.9, p = 0.03). Conclusions: Preoperative GGT may be an inexpensive and easily applicable prognostic indicator in early-stage non-small-cell lung cancers.

Second Cancers Occurring in Patients With Early Stage Non–Small-Cell Lung Cancer Treated With Chest Radiation Therapy Alone

2001 ◽  
Vol 19 (4) ◽  
pp. 1056-1063 ◽  
Author(s):  
Branislav Jeremic ◽  
Yuta Shibamoto ◽  
Ljubisa Acimovic ◽  
Nebojsa Nikolic ◽  
Aleksandar Dagovic ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Second Cancer ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Second Cancers

PURPOSE: To investigate the incidence of second cancers occurring in patients with early stage (I/II) non–small-cell lung cancer (NSCLC) treated with radiation therapy (RT) alone.PATIENTS AND METHODS: Seventy-eight patients had been treated with conventionally fractionated (CF) RT (1982 to 1987), and 116 patients had been treated with hyperfractionated (Hfx) RT (1988 to 1993). Tumor doses were 60 Gy for CF and 69.6 Gy (1.2 Gy bid) for Hfx.RESULTS: A total of 26 patients developed second cancers. The cumulative incidence of second cancer was 21.8% (SE, 4.7%) at 5 years and 34.8% (SE, 6.7%) at 10 years. For second lung cancers, it was 6.0% (SE, 2.8%) at 5 years and 14.2% (SE, 5.2%) at 10 years, and for second nonlung cancers, it was 16.3% (SE, 4.2%) at 5 years and 22.2% (SE, 5.7%) at 10 years. The rate of developing second cancer per patient per year was 4.3% (95% confidence intervals [CI], 2.7% to 5.9%), with the rates being 1.4% (CI, 0.5% to 2.3%) for the second lung cancers and 2.8% (CI, 1.5% to 4.1%) for second nonlung cancers. The rate of developing second cancers during the first and second 5-year period after RT (0 to 5 and 5 to 10 years) was 4.3% (CI, 2.4% to 6.2%) and 4.2% (CI, 0.6% to 7.8%), respectively, for all cancers. These rates were 1.0% (CI, 0.1% to 1.9%) and 2.2% (CI, 0% to 4.6%), respectively, for second lung cancers, and 3.2% (CI, 1.6% to 4.8%) and 1.5% (CI, 0% to 3.6%), respectively, for second nonlung cancers.CONCLUSION: Long-term survivors after RT alone for early stage NSCLC carry the same risk of developing second cancer, either lung or nonlung, as their counterparts treated surgically when the results of this study are compared with those of the published literature.

scholarly journals Apoptosis Gene Expression Profile in Early-Stage non Small Cell Lung Cancer

2010 ◽  
Vol 13 (2) ◽  
pp. 47-52
Author(s):  
S Metodieva ◽  
R Cherneva ◽  
D Nikolova ◽  
G Genchev ◽  
D Petrov ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Gene Expression Profile ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung ◽  
Early Stage Nsclc ◽  
Apoptosis Gene

Apoptosis Gene Expression Profile in Early-Stage non Small Cell Lung CancerNon small cell lung cancer (NSCLC) is a highly aggressive malignancy with survival rates limited to some patients in early stages (I and II). Apoptosis resistance is a hallmark of solid tumors that is tightly concerned with their biology. We analyzed the expression of 84 apoptosis-related genes in a group of Bulgarian patients with early-stage NSCLC.RNA samples extracted from 12 early-stage NSCLC patients [five squamous cell carcinomas (SCC) and seven adenocarcinomas (AC)] and eight adjacent non neoplastic pulmonary tissues were used for gene expression analysis. We applied pathway-focused expression profiling of 84 apoptosis-related genes using real-time PCR.Apoptosis-related genes down regulated in NSCLC compared to non tumor lung tissue (p <0.05) included representatives of the tumor necrosis factor (TNF) ligand family [TNF superfamily 8 (TNFSF8)], caspase cascade (CASP8 and CASP10) and caspase recruitment domain (CARD) family (BCL10), the positive apoptosis regulator DAPK1 and BCL2 family member MCL1. The potential of apoptosis-related genes as prognostic and predictive markers should be validated in future studies.

scholarly journals Evaluating Treatment strategies for Non-small Cell Lung Cancer during COVID-19: A Propensity Scores Matching Analysis

2021 ◽  
Author(s):  
Minhao Yu ◽  
Yalin Cheng
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Progression ◽  
Cell Lung Cancer ◽  
Late Stage ◽  
Propensity Scores ◽  
Early Stage ◽  
Treatment Strategies ◽  
Small Cell ◽  
Small Cell Lung

Abstract Background We had different understanding of treatment strategies to which we preferred conduct surgery for early-stage patients and delay treatment for late-stage non-small cell lung cancer patients at beginning of the COVID-19 pandemic. However, as we learned more about other guidelines, we were not sure whether our strategies have caused adverse results. Methods We divided patients hospitalized from September 2019 to February 2020 into experimental and control groups, and evaluated treatment strategies by patients’ prognosis. Propensity scores matching was used to adjust selection bias. Results Therapy discontinuation in the experimental group were significantly higher than the control group (P༜0.001). The differences of cancer progression and the number of deaths between the two groups were not significant (P = 0.376, 0.128, respectively). There were significant differences in non-surgical treatment and discontinued therapy for late-stage patients (P༜0.001, ༜0.001, respectively), while the differences of surgical treatment and therapy discontinuance for early-stage patients were not significant (P = 0.243, 0.243, respectively). The cancer progression and death toll differences in both early and late stage between the two groups were not significant (P = 0.608, 0.489, 0.197, 0.197, respectively). Multivariate analysis revealed therapy discontinuation did not predicted progress-free survival independently (hazard ratio = 1.007, 95% confidence interval: 0.653–1.552, P = 0.976). Conclusions For patients in regions with low risk for COVID-19 infections, surgery should not be delayed for early-stage patients if the hospital has adequate medical resources and strict testing and prevention measures are utilized. Delaying treatment less than three months can not significantly impact the prognosis of late-stage non-small cell lung cancer patients.

Sign in / Sign up

Export Citation Format

Share Document